Obsolete test for prostate cancer screening; preferred test is total prostate specific antigen (0070121
) in conjunction with digital rectal exam.
Quantitative Chemiluminescent Immunoassay
This test is New York DOH approved.
The Siemens Immulite2000 PAP chemiluminescent immunoassay method is used. Results obtained with different assay methods or kits cannot be used interchangeably. PAP may be of some use in predicting disease recurrence or monitoring treatment effects. It has little clinical utility as a screening test for prostate cancer. Prostate specific antigen (PSA) is the preferred test for prostate cancer screening, monitoring, and predicting outcomes. Benign prostatic hyperplasia, prostate massage, and prostatic infarction may result in elevated PAP concentrations. The PAP assay value, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease.